Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
TEM: Notice of proposed sale of Restricted Stock Units. The filing lists 13,583 Restricted Stock Units to be sold by the issuer with an effective date of
The filing also shows prior sales by James Rogers: 10,084 common shares sold on
TEM reported an insider sale filing to sell 870 restricted common stock units. The transaction is described as restricted stock units to be sold by the issuer on
The filing also lists a prior 10b5-1 sale of 370 common shares on
Tempus AI, Inc. executive Thomas Edward Schoenherr, CEO of Diagnostics, reported beneficial ownership of 94,967 shares of Class A common stock in an initial insider filing. This amount includes 54,405 restricted stock units, which vest in scheduled installments through February 15, 2028, and 20,000 shares certified as earned from performance-based stock units granted on August 7, 2025. The performance-based units are scheduled to vest on August 15, 2026 after the board certified achievement of the required performance metrics on February 20, 2026.
Tempus AI, Inc. outlines in its Annual Report how it uses artificial intelligence to build “Intelligent Diagnostics” that connect lab results with each patient’s clinical data to guide treatment decisions. The company has two main product lines: Diagnostics (oncology, hereditary and other tests) and Data and applications (including Insights, Trials, Next and Algos).
Its Platform aggregates multimodal data at scale through more than 700 data connections and over 5,000 healthcare sites, producing de-identified datasets used by providers and 19 of the 20 largest pharmaceutical companies. As of December 31, 2025, contracts in its data business had Remaining Total Contract Value of more than
The report highlights expansion beyond oncology into neurology and cardiology, a growing suite of algorithmic diagnostics, and acquisitions such as Ambry Genetics, Arterys and Paige to deepen hereditary testing and imaging capabilities. The aggregate market value of non‑affiliate equity was approximately
Tempus AI reported very strong growth for Q4 and full-year 2025 while remaining unprofitable on a GAAP basis.
Revenue rose
The company posted a 2025 net loss of
Tempus AI, Inc. director, CEO and Chairman Eric P. Lefkofsky reported a mix of stock awards and sales involving Class A Common Stock. He acquired 263,430 shares at no cost through a grant that includes fully vested restricted stock units and performance-based stock units certified as earned.
Entities associated with Lefkofsky, including Gray Media, LLC and Blue Media, LLC, sold a combined 179,837 shares in open-market transactions under a Rule 10b5-1 trading plan. In addition, 13,587 directly held shares were sold to cover statutory tax withholding obligations tied to vesting of restricted stock units, a mandated sell-to-cover transaction rather than a discretionary sale.
Tempus AI, Inc. executive vice president and chief administrative officer Erik Phelps reported selling a total of 9,464 shares of Class A common stock in open-market transactions on February 19, 2026. The reported sale prices were about $60.00 and $59.05 per share, leaving him with 79,816–85,466 shares after the trades, as shown per line item. The filing notes that at least one transaction was executed under a pre-arranged Rule 10b5-1 trading plan, and that a portion of shares was sold to cover statutory tax withholding obligations related to restricted stock unit vesting rather than as a discretionary sale.
Tempus AI, Inc. Chief Accounting Officer Ryan M. Bartolucci reported two equity transactions in Class A common stock. On February 20, 2026, he acquired 12,998 shares at no cost as equity compensation. This comprises 2,998 fully vested restricted stock units for his 2025 bonus and 10,000 performance-based stock units certified as earned, which are scheduled to vest on August 15, 2026 after the board certified performance goals.
On February 19, 2026, he sold 2,902 shares at a weighted average price of $59.05 per share. According to the disclosure, this was a mandatory “sell-to-cover” transaction to satisfy statutory tax-withholding obligations on vesting RSUs, and not a discretionary sale.
Tempus AI, Inc. executive Andrew Polovin reported a mix of equity awards and related share sales in Class A common stock. He acquired 38,420 shares on
The award includes 5,120 fully vested restricted stock units as his 2025 bonus and 33,300 performance-based stock units certified as earned, with those PSUs scheduled to vest on
Additional open-market sales totaling 19,092 shares occurred on
Tempus AI, Inc. executive Ryan Fukushima, Chief Executive Officer, Data, reported both an equity award and a related tax-sale transaction in Class A common stock. He acquired 74,993 shares at $0.00 per share as a grant/award, consisting of 8,393 fully vested restricted stock units as his 2025 bonus and 66,600 shares earned from performance-based stock units granted on August 7, 2025, after the board certified performance on February 20, 2026. Separately, he sold 9,592 shares on February 19, 2026 at a weighted average price of $59.05, in multiple trades between $58.71 and $59.38, solely to cover statutory tax withholding obligations under a mandated “sell to cover” election, not as a discretionary sale. After these transactions, he directly owned 769,347 shares, and an additional 148,808 shares were reported as indirectly owned by his spouse.